From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.
We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
In this webinar, get a comprehensive overview of the UK’s biotech and life sciences presence at BIO 2025. Learn about the UK delegation’s plans, including the UK Pavilion organised by the Department for Business and Trade.
Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus has been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the MHRA.
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
BIA has responded to the DBT's consultation on potential UK tariffs in response to US measures, urging to protect life sciences supply chains, innovation, and patient access.
This report is the first step in understanding the specific challenges faced by female CEOs and C-suite in biotechnology in the UK – in order to understand best how we can help to enact change and provide relevant support.
In our submission, we reiterate the economic growth potential of UK life sciences, and welcome its recognition within the Industrial Strategy as a priority sector. We call for government to turn its attention to the six key areas outlined within the Industrial Strategy, and list a number of priority investments within them.
We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.
The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.
2024 continues to be a big year for US politics. As well as a presidential election, there are several pieces of legislation that either are affecting or will affect our sector. Watch the recording to learn more about all three of these developments, and what it will mean for you as a UK biotech.
In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, recaps the recent Women in Biotech event in Manchester, where industry leaders discussed talent attraction, female leadership, and career advancement. The panel highlighted the importance of fostering home-grown talent, supporting female role models, and offering mentorship opportunities.
Coulter Partners recently partnered with QBiotics Group Limited (QBiotics) and is pleased to announce the placement of new senior leadership team members.
